{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-014649","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2022-04-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.267233+00:00","generated_at":"2026-06-26T07:02:34.804335+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma establishes Special Committee to evaluate strategic options","bullets":["Special Committee formed to explore options for maximizing stockholder value.","Committee includes Board Chairman Robert E. Conway (chair), Linda Grais, and Anders Hove.","Company believes multiple opportunities exist to enhance value, but no specific deal disclosed.","No timeline given for completion of strategic review."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-014649","json":"https://secwatch.observer/filing/0001564590-22-014649.json","markdown":"https://secwatch.observer/filing/0001564590-22-014649.md","text":"https://secwatch.observer/filing/0001564590-22-014649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000156459022014649/0001564590-22-014649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000156459022014649/abio-8k_20220418.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T07:02:34.804335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}